key: cord-0848752-cgdnd36r authors: Sarkis, Julien; Samaha, Ramy; Kattan, Joseph; Sarkis, Pierre title: Bladder cancer during the COVID-19 pandemic: the calm before the storm? date: 2020-08-03 journal: Future science OA DOI: 10.2144/fsoa-2020-0101 sha: 16530435c934353903f1290afa4a70440fa92fd6 doc_id: 848752 cord_uid: cgdnd36r nan Even patients already diagnosed with bladder cancer can see their treatment (transurethral resection of bladder tumor, intravesical instillations or radical cystectomy) delayed. Transurethral resection of bladder tumor, the cornerstone management of nonmuscle invasive bladder cancer (NMIBC), has no current alternative [14] . However, during this critical period during which hospital beds must be released to accommodate the influx of COVID-19 positive patients, admissions to the urology, oncology or radiotherapy departments are being avoided [13] . Consequently, cancer committees have drawn up recommendations to distinguish NMIBC requiring urgent treatment from those whose treatment can be deferred [15] . Validated clinical and pathological criteria (previous history, tumor size and number) can help physicians in evaluating which tumors necessitate urgent resection from those that can be deferred. But even in low-risk cases, resection cannot be postponed for more than 3 months [15] . Patients may therefore find it difficult to meet this timeline and cancer progression may be observed. This problem is even more encountered in high-risk NMIBC patients as they require regular hospital visits for intravesical therapy. The latter, like Bacillus Calmette-Guerin (BCG) instillations, cannot be reduced [16] despite the current crisis. And finally, due to operating room closure and saturation of ICU beds, muscle-invasive bladder cancer patients awaiting their radical cystectomy are seeing their surgery delayed [9] . This is problematic, especially for patients on neoadjuvant chemotherapy as a delay of more than 3 months may have a negative impact on prognosis [17] . Some muscle-invasive bladder cancer patients may even undergo suboptimal treatment like radiotherapy and chemotherapy instead of surgery. Solutions must be rapidly identified as delay in BC management will cause fatal progression of the disease and presentation at a more advanced stage, which will eventually require urgent hospital admission. Patients should know that the risks of delayed emergency conditions due to BC can be much higher than those posed by COVID-19. Measures that raise patient awareness and allow care at home like telemedicine and telephone calls should be encouraged [18] . Patient's follow-up must be preferably performed by teleconsultation to avoid their displacements and in case of BC suspicion, physicians must be able to assure primary diagnostic tests like urine cytology, urine culture and ultrasonography in COVID-19 free centers to ensure patient's safety. A safe environment should also be insured for BC patients under instillation therapy (BCG or chemotherapy), as their regular hospital visits may expose them to the virus. On another note, because complex cases and life-saving surgeries are being postponed, it is essential to maintain traceable multidisciplinary discussions [19] . The latter can also propose evidencebased alternatives for surgeries, without compromising prognosis. Recently US FDA approved pembrolizumab, for example, can be discussed in BCG-unresponsive, high-risk, NMIBC with carcinoma in situ that cannot undergo cystectomy (Phase II KEYNOTE-057 trial [20] ) because of closed operating rooms or saturated ICU beds. The anticipated rise in bladder cancer in the following months is another face of the global public health impact of COVID-19. Delayed cancer diagnoses and management during the pandemic, risks many thousands of BC cases going undetected and untreated, causing a surge in untreated BC incidence in the coming months. This surge in advanced bladder cancer, as well as the knock-on effects (rise in demand for cancer-related services once the pandemic has passed), "could overwhelm health services and contribute to an excess in cancer-related mortality in the coming years"' [10] . A practical proactive approach must be started now, more than ever to delay what would possibly be the real 'second wave' of deaths due to COVID-19. A novel coronavirus from patients with pneumonia in China Coronavirus update (Live): 4,952,763 cases and 323,017 deaths from covid-19 virus pandemicworldometer (2020) Clinical characteristics of coronavirus disease 2019 in China A review of coronavirus disease-2019 (COVID-19) High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy What the oncologist needs to know about COVID-19 infection in cancer patients The Lebanese Society of Medical Oncology (LSMO) statement on the care of patients with cancer during the COVID-19 pandemic Safeguarding cancer care in a post-COVID-19 world The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection Severe outcomes among patients with coronavirus disease 2019 (COVID-19) -United States Minimizing intra-hospital transmission of COVID-19: the role of social distancing EAU guidelines: non-muscle-invasive bladder cancer Studie zur Therapie beim nicht-muskelinvasiven Blasenkarzinom Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer and its impact on surgical morbidity and oncological outcomes: a real-world experience Virtually perfect? Telemedicine for COVID-19 Cancer multidisciplinary team meetings: evidence, challenges, and the role of clinical decision support technology Keynote 057: phase II trial of pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG)